Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 28

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---

A
summary of the status of the Company’s nonvested RSUs as of June 30, 2024, and changes during the three and six months ended
June 30, 2024, is presented below:

    Non-vested
    RSUs
     
    RSUs

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    25,710

    $
    13.00

    Vested

    —

    $
    —

    Forfeited

    —

    $
    —

    Non-vested at
    June 30, 2024

    25,710

    $
    13.00

A
summary of the status of the Company’s nonvested RSUs as of June 30, 2025, and changes during the three and six months ended
June 30, 2025, is presented below:

    Non-vested
    RSUs
     
    RSUs

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31, 2024

    29,219

    $
    10.80

    Granted

    —

    —

    Vested

    (9,270
    ) 

    (11.82
    )

    Forfeited

    —

    —

    Non-vested at June 30, 2025

    19,949

    $
    10.67 

    20 

The
total number of RSUs granted during the three months ended June 30, 2025 and 2024 was 0 and 25,800
respectively. The total number of RSUs granted during the six months ended June 30, 2025 and 2024 was 0 and 25,800
respectively. 

The
Company recognized stock-based compensation expense related to RSU vesting amortization of $51,910 and $13,975 for the
three months ended June 30, 2025 and 2024, respectively, which is included in general and administrative expenses in the condensed
consolidated statements of operations. The Company recognized stock-based compensation expense related to RSU vesting amortization
of $103,820 and $13,975 for